LONDON, April 20, 2017 /PRNewswire/ --
BTG plc (LSE: BTG), a global specialist healthcare
company, today announced the treatment of the first patients in the
EU with DC Bead LUMI™. Two patients were treated for hepatocellular
carcinoma (HCC) and one patient was treated for malignant
colorectal cancer metastasised to the liver (mCRC). DC Bead LUMI™
is the first commercially available radiopaque drug-eluting bead
(DEB) in the EU which can be loaded with doxorubicin or irinotecan
for the local treatment of tumours in patients with HCC and mCRC,
respectively. DC Bead LUMI™ is a next-generation development of DC
Bead®, the market leading drug-loadable embolic
bead.
(Logo:
http://photos.prnewswire.com/prnh/20160203/329110LOGO )
At the Istituto Oncologico Veneto, Padova, Italy, Dr Camillo
Aliberti, Director of Radiology, and his team performed
transarterial chemoembolisation (TACE) procedures using DC Bead
LUMI™, enabling real-time, visible, lasting confirmation of bead
location during and post-embolisation of tumours in the liver.
"We are very pleased with the results from treatment in our
patients, and DC Bead LUMI™ offered clear, real-time evidence on
the treatment of the target lesion while the long-term radiopacity
means not only can we see where we are delivering the treatment
during the procedure, but we can also identify areas of successful
treatment - or under treatment - in follow up scans." said Dr
Aliberti.
Next Step in BTG Interventional Oncology
Strategy
Liver cancer is the second leading cause of cancer deaths in the
world[1], and one of the most
challenging to treat. Each year, more than 700,000 patients
worldwide are diagnosed with liver
cancer.[2] Interventional
embolisation is an option for some patients with tumours that
cannot be removed by surgery.
"DC Bead LUMI™ provides the opportunity to individualise a
patient's treatment and bring a new level of control to TACE
procedures. At the same time, the lasting radiopacity allows you to
see rather than assume the location of the beads, providing
reassurance to patients that the treatment is getting to where it
needs to be." commented Duncan
Kennedy, BTG Head of Interventional Oncology. "DC Bead LUMI™
is the latest step of BTG Interventional Oncology's strategy to
discover and develop differentiated therapeutic innovations. The
feedback from the treatment of the first patients indicates that DC
Bead LUMI™ is an important advance in personalised, loco-regional
cancer therapies. We're proud to offer an innovative new treatment
option for patients and clinicians and look forward to providing DC
Bead LUMI™ to more clinicians across the EU."
DC Bead LUMI™ gained Class III CE Mark certification in early
March, 2017.
About BTG Interventional Medicine
BTG Interventional Medicine is part of BTG plc, a growing
international specialist healthcare company. As medicine moves from
major surgery to minor procedure, from the systemic to the local,
no company endeavors to do more than BTG Interventional Medicine to
help doctors in their quest to see more, reach further and treat
smarter. Our growing portfolio of Interventional Medicine products
is designed to advance the treatment of liver tumors, advanced
emphysema, severe blood clots, and varicose veins. To learn more
about BTG Interventional Medicine, please visit: btg-im.com.
About DC Bead LUMI™
DC Bead LUMI™ is the first commercially available radiopaque
drug-eluting bead (DEB) which can be loaded with doxorubicin or
irinotecan for the local treatment of tumours in patients with
hepatocellular carcinoma (HCC) and malignant colorectal cancer
metastasised to the liver (mCRC). DC Bead LUMI™ are precisely
calibrated, radiopaque DEB developed using the same core chemistry
as the clinically proven DC Bead®. DC Bead LUMI™ contain
a covalently bound radiopaque moiety to offer inherent, lasting
radiopacity; they are visible under imaging (computed tomography
[CT], cone-beam computed tomography [CBCT] and fluoroscopy)
providing visible confirmation of bead location during embolisation
procedures. The lasting radiopacity of DC Bead LUMI™ means they
will also be visible in follow-up scans. For more information,
please visit: dcbeadlumi.com.
About DC Bead®
DC Bead® is the only drug-eluting bead with CE Mark
approval for loading with doxorubicin or irinotecan, providing an
effective standardised liver-directed therapy for primary and
metastatic liver cancer. With more than ten years' clinical
experience, extensive peer-review evidence supports the benefits
offered by the unique chemistry of DC Bead®. In intermediate HCC,
these benefits include improved tolerability and tumour response
versus cTACE and high rates of five-year
survival.[3]-[7]
In metastatic colorectal cancer patients, DC Bead® has been shown
to offer improved survival and enhanced quality of life versus
systemic chemotherapy alone.[8]
For instructions for use and important safety information, please
visit: dcbead.com.
For further information contact:
BTG plc
Chris Sampson, Corporate
Communications
+44-(0)-20-7575-1595; Mobile: +44-7773-251-178
Email: chris.sampson@btgplc.com
Media Liaison
Jonathan Falcone
+44-(0)-20-8618-2752; Mobile: +44-7825-238-898
Email: j.falcone@togorun.com
References:
[1] World Health Organization
(WHO). Cancer factsheet. Available at:
http://www.who.int/mediacentre/factsheets/fs297/en/. Last accessed
April, 2017.
[2] American Cancer Society. What are the key
statistics about liver cancer?. Available at:
http://www.cancer.org/cancer/livercancer/detailedguide/liver-cancer-what-is-key-statistics.
Last accessed April, 2017.
[3] Lammer J et al. Cardiovasc Intervent
Radiol 2010; 33: 41-52.
[4] Song MJ et al. Eur J Gastroenterol
Hepatol 2011; 23: 521-7.
[5] Dhanasakeran R et al. J Surg Oncol 2010;
101: 476-80.
[6] Burrel M et al. J Hepatol 2012; 56:
1330-5.
[7] Malagari K et al. Cardiovasc Intervent
Radiol 2012; 35: 1119-28.
[8] Fiorentini G et al. Anticancer Res 2012;
32: 1387.
